Avista Healthcare Partners

Overview

Avista Healthcare Partners is a New York-based private equity firm specializing in healthcare investments. Founded in 2005, the firm has invested over $9 billion in more than 50 growth-oriented healthcare businesses globally. Avista focuses on healthcare product and technology companies with clear scale potential across various sub-sectors, including outsourced pharma and medtech services, consumer healthcare, medical devices, specialty and generic pharmaceuticals, distribution and diagnostics, and healthcare technology. The firm partners with businesses that have strong management teams, stable cash flows, and robust growth prospects. Avista's investment strategy involves a high-touch approach to value creation, collaborating closely with management teams to drive growth and performance. This strategy has resulted in a 115% weighted average revenue growth across its investments. The firm has a team of over 30 professionals, including dedicated strategic executives with vast operational expertise at leading healthcare companies. Avista's most recent fund, Avista Healthcare Partners VI, closed in March 2024 at $1.5 billion, significantly exceeding its $1.25 billion target. This fund focuses on high-growth middle-market product and technology healthcare companies in North America and Europe. In June 2025, Avista closed a continuation fund for GCM, a leading outsourced manufacturer of complex precision components for medical technology end markets. This continuation fund, managed by Avista, was anchored by commitments from funds managed by Goldman Sachs Alternatives and BlackRock Secondaries & Liquidity Solutions. The fund includes substantial unfunded capital commitments to support acquisition opportunities and strategic investments for GCM. Since acquiring GCM in 2019, Avista has partnered with management to expand the company's manufacturing and commercial capabilities through critical investments in technology, facilities, and human capital, while also growing the company's customer base across attractive medical technology end markets. In June 2025, Avista acquired EBI, the bone healing division of Highridge Medical, marking its 50th platform healthcare investment. EBI is a pioneer in electrobiology innovations, offering a robust portfolio of clinically proven implantable and non-invasive bone growth stimulation solutions. This acquisition underscores Avista's commitment to building category-leading healthcare businesses and its ability to execute complex corporate carve-outs. The firm's strategic approach and deep operational expertise continue to drive growth and performance in the healthcare sector, creating long-term value and sustainable businesses. In July 2024, Avista and funds managed by Hamilton Lane acquired a significant equity interest in Cosette Pharmaceuticals, a U.S.-based specialty pharmaceutical company. This partnership aims to accelerate innovation and growth at Cosette, leveraging Avista's long-term relationship with Hamilton Lane to drive value creation. Since Avista's initial investment in Cosette in December 2018, the company has successfully launched new and innovative products across its portfolio through significant R&D efforts, acquisitions, and licensing deals, including the recent acquisition of Ambien® and Ambien CR® in the United States from Sanofi US. These initiatives have led to robust EBITDA growth and positioned Cosette to capitalize on compelling opportunities ahead. Avista's commitment to the healthcare sector is further demonstrated by its rebranding from Avista Capital Partners to Avista Healthcare Partners in August 2024. This name change reflects the firm's established position as a premier healthcare investor with a 20+ year track record of investing in and building leading products and technology-focused healthcare businesses. The rebrand aligns the firm's identity with its investment focus and reinforces its commitment to the healthcare sector. Overall, Avista Healthcare Partners

Portfolio Companies